Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials.


As an international cooperation, we have established offices in different countries and districts with experienced scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established our leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. We offer our customers with comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation. Furthermore, our inventory also contains an extensive list of linkers, payloads, payload-linker sets, and commonly used ADCs for quick deployment and concept validation.


Immunotherapy has entered a stage that is dominated by the ADC-based targeted therapy or precision medicine. With a large number of ADCs entering clinical test, it is obvious that the dawn of ADC has begun. With our integrated global resources in all aspects, our one-stop ADC development services will provide you with a platform that could exponentially speed up the process of ADC development, from ADC formulation to clinical evaluation, and ultimately promote science for the cause of a better tomorrow.